Should I Buy Verve Therapeutics (VERV)? Finance YouTuber Analysis

The speaker notes Verve Therapeutics' collaboration with Beam Therapeutics to utilize base editing for treating hypercholesterolemia. This approach, if successful in clinical trials, could initially help high-risk patients and potentially be expanded to a wider population, addressing heart disease, which is the leading cause of death. This represents a significant long-term opportunity.

“a great example of this is the collaboration between verve therapeutics and beam therapeutics to use base editing to treat hypercholesterolemia by editing pcsk9”

Verve Therapeutics is developing a one-and-done gene-editing medicine to permanently lower LDL cholesterol, addressing the leading cause of death worldwide. The company has shown promising preclinical data in monkeys for its VERVE-101 program targeting PCSK9, demonstrating significant and durable LDL reduction. They also have a pipeline of other gene-editing targets and are focused on making these therapies cost-effective and accessible to millions of patients.

“Our company is founded on the idea that we can develop a one and done gene editing medicine that would lower ldl cholesterol dramatically and do so for essentially a lifetime durably do so and as a way to treat treat heart attack.”